Study Phase 2

An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer

Trial Information

Generic NameErdafitinibProduct NameBALVERSA®Therapeutic AreaAntineoplastic and Immunomodulating AgentsProduct ClassAntineoplastic AgentsPharmacological SubgroupProtein Kinase InhibitorsChemical SubgroupFibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase InhibitorsCondition StudiedUrothelial Cancer
Sponsor Protocol Number42756493BLC2001Enrollment239Data PartnerJohnson & Johnson% Female29.1%Mean/Median Age (Years)65.8% White73.8%

Supporting Documentation

  • Collected Datasets Available
  • Data Definition Specification Available
  • Protocol with Amendments Available
  • Statistical Analysis Plan Available
  • Clinical Study Report Available

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.